
Please try another search
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Mark Evans | - | 2020 | Member of Scientific Advisory Board |
Jens Juul Holst | - | 2013 | Member of Scientific Advisory Board |
Richard Busellato | 58 | 2023 | Independent Director of the Board |
Arpad Szallasi | - | 2013 | Member of Scientific Advisory Board |
Dorte Xenia Gram | 56 | 2014 | Founder, Chairman & Chief Scientific Officer |
Carolyn F. Deacon | - | 2013 | Member of Scientific Advisory Board |
Soren Weis Dahl | 59 | 2023 | Independent Director of the Board |
Julie Waras Brogren | 53 | 2024 | Director |
Lasse Richter Petersen | - | 2024 | Director |
Jens Viktor Norgaard | - | 2016 | Member of Scientific Advisory Board |
Bo Ahrén | - | 2013 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review